心脏结节病患者临床特征与预后的性别差异
本研究为ILLUSTRATE注册研究的二次分析,纳入2001至2017年512例心脏结节病患者,女性占64.2%,两性诊断高峰年龄均为60-64岁。中位随访3年,99例发生潜在致死性室性心律失常事件,男性风险显著高于女性(p=0.002),校正左室射血分数等危险因素后仍显著(校正HR 1.80;95%CI 1.08至3.01,p=0.025)。
要点
- 心脏结节病患者中约三分之二为女性,两性诊断高峰年龄约60岁。
- 男性患者较女性年轻,冠心病患病率更高,左室射血分数更低。
- 男性患者潜在致死性室性心律失常事件风险显著高于女性。
核心结论
- 男性心脏结节病患者潜在致死性室性心律失常事件风险显著高于女性,校正其他危险因素后关联仍存在。
研究设计与样本
- 本研究为ILLUSTRATE注册研究的二次分析,该注册为回顾性多中心注册,纳入2001至2017年间512例心脏结节病患者。
主要发现
- 512例患者平均年龄61.6±11.4岁,女性329例(64.2%),两性诊断高峰年龄均为60-64岁。
- 男性患者较女性年轻,冠心病患病率更高,左室射血分数更低。
- 中位随访3年(IQR 1.6-5.6),99例发生潜在致死性室性心律失常事件,男性风险显著高于女性(p=0.002)。
- 校正左室射血分数等危险因素后,男性与潜在致死性室性心律失常事件的关联仍显著(校正HR 1.80;95%CI 1.08至3.01,p=0.025)。
临床怎么用
- 在评估心脏结节病患者室性心律失常风险时,应考虑性别差异,男性患者风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Owing to the paucity of data, this study aimed to investigate sex differences in clinical features and prognosis of patients with cardiac sarcoidosis (CS). METHODS: This study was a secondary analysis of the ILLUstration of the Management and prognosIs of JapaNese PATiEnts with Cardiac Sarcoidosis registry-a retrospective multicentre registry that enrolled patients with CS between 2001 and 2017. The primary outcome was potentially fatal ventricular arrhythmia events (pFVAEs)-a composite of sudden cardiac death, sustained ventricular tachycardia lasting >30 s, ventricular fibrillation or the requirement for implantable cardioverter defibrillator therapy. RESULTS: Of the 512 participants (mean age±SD 61.6±11.4 years), 329 (64.2%) were females. Both sexes had peak ages of 60-64 years at diagnosis. Male patients were younger and had a higher prevalence of coronary artery disease and lower left ventricular ejection fraction than female patients. During a median follow-up of 3 years (IQR 1.6-5.6), pFVAEs were observed in 99 patients, with males having a significantly higher risk than females (p=0.002). This association was retained even after adjustment for other risk factors for pFVAEs, including left ventricular ejection fraction (adjusted HR 1.80; 95% CI 1.08 to 3.01, p=0.025). CONCLUSION: Approximately two-thirds of patients with CS were females, with a peak age of approximately 60 years at clinical diagnosis in both sexes; male patients were younger than female patients. Male patients had a significantly higher risk of pFVAEs than female patients. TRIAL REGISTRATION NUMBER: UMIN000034974.
引用
- Iso T, Maeda D, Matsue Y, et al. Sex differences in clinical characteristics and prognosis of patients with cardiac sarcoidosis. Heart. 2023. PMID: 37185298. doi:10.1136/heartjnl-2022-322243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。